· Net sales: SEK 20.8 million (SEK 24.4 million, full year 2013) · EBITA: SEK -4.7 million (SEK -15 million, full year 2013) · Operating loss: SEK 10 million (SEK 24.3 million, full year 2013) · Loss after tax: SEK 10.5 million (SEK 25.4 million, full year 2013) · Earnings per share: SEK -0.24 (SEK -2.94, full year 2013) Events during the period · In January, CybAero received its largest order to date with a value of EUR 5.5 million. The order is for the delivery of a small number of systems to be operated from ships with China Customs being the end user. · In February, the final delivery of orders on hand to CybAero's U.S. partner AeroVironment was completed. · In March, AeroVironment chose to convert one of its two convertible loans to CybAero, each worth SEK 10 million, giving them 1,062,699 shares, which is equal to ownership in the company of just over 8.5%. · In April, CybAero received an order for a demo system from its agent in China. · In April, CybAero held a directed share issue to four international institutional investors. In total, 1.8 million shares were issued, which is equal to approximately 14.4% of CybAero's total share capital. The share issue brought in approximately SEK 50 million for CybAero before issuing costs. Key events after the period · On July 2, the company announced a framework agreement with one of the world's largest companies and aircraft manufacturers, Chinese AVIC. The agreement spans eight years and has a minimum commitment from AVIC for orders of at least 70 systems worth approximately SEK 700–800 million. · In August, AeroVironment requested conversion of its other convertible loan. · In August, CybAero received a supplementary order from Airbus Defence & Space for avionics and subsystems for the continuing development of their TANAN 300 demonstrator. The half year in summary The first half of 2014 has been even more active than the whole year of 2013. In January, CybAero received its largest order to date with the delivery of a small number of ship-based systems with China Customs as the end user. This is a key breakthrough order that proves our competitiveness in these types of advanced systems. Delivery of the systems is estimated to begin before the end of the year. Also during this period, we continued our intensive marketing efforts geared toward the Chinese market in particular, which led to a framework agreement with Chinese AVIC at midyear. AVIC consists of a group of companies whose activities include the development and production of aircraft, and it is one of the largest companies in the world with over 500,000 employees. The framework agreement stipulates that AVIC commits to ordering at least 70 systems in the next eight years. The estimated order value is a minimum of approximately SEK 700–800 million. This is the largest contract ever in our segment and reinforces our position as the world leader in our product and market segment. We have seen a substantial increase in interest in CybAero from the financial market as well, especially from international institutional investors. We have also seen the company's shareholders consistently increase in number. At midyear, the number of shareholders had increased by around 1,000 to just under 4,000, in comparison to the beginning of the year. We are very pleased to see clear evidence on a daily basis that the market for our systems has really taken off. The order in January as well as the agreement with AVIC are clear signs of this. We are continuing to build partnerships around the world and to pursue our objective of being a global leader. Research and development In the Fall of 2013, we began working hard to upgrade the performance and reliability of our main product, APID 60. This work has progressed over the first half of 2014 and is estimated to be completed in Fall 2014. The company has revised its production strategy and is now planning to perform the final assembly of aircraft and systems in-house and use subcontractors and partners for the assembly of subsystems. Market presence and collaboration agreements In January, we received clear proof of the success of our marketing efforts when we received the EUR 5.5 million order for China Customs. Our agent in China placed an order in April for a demo system, which means even more intense marketing in the Asian market. On July 2, we were able to announce our agreement with Chinese AVIC, which definitively solidifies CybAero's role as a global leader in supplying computer-controlled helicopter-based systems under 200 kg. The collaboration with our partner, Indra, is progressing. Indra's project, Pelicano, in which the APID 60 serves as the framework for the system, is however experiencing a heavy delay in comparison to the original schedule. Net sales and profit In the 2013 fiscal year, CybAero switched to recognizing contractual transactions in proportion to the stage of completion of the transaction, which is called the percentage-of-completion method (see “Accounting policies” below for further details). This resulted in the company reporting negative sales for the second half of 2013 due to the sharply reduced order from AeroVironment which, in large part, was recognized as revenue in the first half of 2013 but was radically reduced at the end of 2013 due to broken-off negotiations with the U.S. Department of State. A comparison between January–June 2014 and January–June 2013 is therefore misleading, which explains why the company chose to compare the half-year numbers for 2014 with the full-year numbers for 2013 in parentheses. Revenues for 2014 are mainly attributable to deliveries and other obligations, mainly to China Customs. Net sales for the period came in at SEK 20.8 million (SEK 24.4 million, full year 2013). Revenues totaled SEK 25.2 million (SEK 34.5 million, full year 2013). The company reported a loss after tax of SEK 10.5 million (SEK 25.4 million, full-year 2013). The loss can be explained by the fact that CybAero continues to be in an intensive development phase to transition the company into an industrial powerhouse with the ability to handle large-scale development and production operations. In addition to one-time costs, recurring personnel costs have increased as a result of new recruitment, mainly in the development, aviation, and production departments. Personnel costs totaled SEK 10.3 million (SEK 14.4 million, full year 2013). Capitalized research and development expenditure was amortized in the amount of SEK 5.2 million (SEK 9.1 million, full year 2013). Investments Gross investments in fixed assets for the period amounted to SEK 9.6 million (SEK 16.8 million, full year 2013). Capitalization of research and development expenditure accounts for SEK 9.1 million (SEK 15.7 million, full year 2013) of investments. Liquidity and cash flow In addition to its standard business operations, the company brought in funds during this period via a directed share issue, which brought in approximately SEK 50 million before issuing costs. The share issue was held in April, and four international institutional investors participated in it. They were Allianz Global Investors, Metzler Asset Management, SSE Opportunities, and Nuveen Investments. In total, 1.8 million shares were issued, which is equal to approximately 14.4% of the company's total share capital. Cash flow for the period was SEK 18.4 million (SEK -6.1 million, full year 2013) and the company's cash and bank balances totaled SEK 26.6 million (SEK 8.2 million, full year 2013). The value of available cash and bank balances (including unutilized overdraft facilities) was SEK 30.6 million (SEK 12.2 million, full year 2013). Employees The company's staff has grown from 23 to 32 plus a dozen or so consultants since the beginning of the year. Seven additional employees have been hired from today's date, which means that we will have 39 employees as of the end of August. We are planning to hire more people in the Fall to be able to meet rapidly-increasing interest in the company's products from international customers. Equity The company held a directed share issue in April. Four international institutional investors subscribed to it and it brought in approximately SEK 50 million before issuing and underwriting expenses. After the share issue, the company's equity totals SEK 60.3 million (12.9, full year 2013). The Company's stock CybAero's stock is listed on the Nasdaq OMX First North. The stock's closing price on June 30, 2014 was SEK 31.00 (SEK 15.50 on December 30, 2013). The company had 14,265,003 shares at the end of the period. Other information Accounting policies The company complies with the Swedish Annual Accounts Act and the general advice of the Swedish Accounting Standards Board. The Company's accounting policies can be found in its 2013 annual report and are unchanged from the previous year. As of the 2013 fiscal year, CybAero recognizes revenues from contractual transactions in proportion to the stage of completion of the transaction in compliance with BFNAR 2000:2 Application of the Swedish Financial Accounting Standards Council's Recommendations and Opinions as well as the Swedish Financial Accounting Standards Council's recommendation RR10 Construction Contracts and Similar Contracts. The percentage-of-completion method presents a more true and fair view of the company's earnings during the fiscal year. The comparison year has not been converted. Financial calendar The year-end report for 2014 will be presented on February 27, 2015. These interim financial statements have not been audited by the company's auditors. Linköping. August 22, 2014 The Board of Directors of CybAero AB via Mikael Hult, CEO For more information, please contact: Mikael Hult, CEO CybAero AB, tel: +46 (0)70-564 25 45, email: mikael.hult@cybaero.se Anna-Lena Rahm, CFO CybAero AB, tel: +46 (0)70-635 15 60, email: anna -lena.rahm@cybaero.se Read more online: www.cybaero.se Videos: www.youtube.com/cybaero About CybAero CybAero AB develops, manufactures and markets autonomous unmanned helicopters (VTOL UAVs) with associated sensor systems for use in both civil and military applications. CybAero was founded in 2003, but the foundations of its business were laid in 1992 through a research collaboration between Linköping University and the Swedish Defense Research Agency (FOI). With APID trademark, CybAero is now established as a global VTOL UAV leader. The Company's APID product attracts much attention globally for being user-friendly, robust and price-efficient. CybAero's head office is in the Mjärdevi Science Park in Linköping, Sweden. The company has just over 40 employees and is listed on the NASDAQ OMX First North. Remium Nordic AB (tel. 08-454 32 00) is the company's certified advisor.
Semi-Annual Report January–June 2014 CybAero AB (publ)
Top 10 Most Recent News Articles
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue ReadingTop 5 Most Recently Viewed Articles
Empowering Women Through the Gettysburg Salon Experience
Reimagining Women's Spaces Through the Gettysburg Salon The Gettysburg Salon is a vibrant platform where women can express themselves creatively and engage in thought-provoking dialogues. This initiative began with three passionate individuals who envisioned a safe space for women to explore their identities, aspirations, and challenges through art and conversation. In a...
Continue Reading
Transforming Off-Road Adventures: Upfit UTV and OMI Innovation
Transforming Off-Road Adventures: Upfit UTV and OMI Innovation Upfit UTV, a subsidiary of Fox Factory known for customizing high-performance vehicles, has joined forces with OMI, a leader in electric powertrain engineering. Together, they are redefining off-road adventures with their groundbreaking Fusion-Drive technology. This innovation not only elevates performance but...
Continue Reading
Investor Alert: AstraZeneca Faces Class Action Lawsuit Under SEC Laws
Investor Alert Regarding AstraZeneca Securities Class Action Kahn Swick & Foti, LLC, founded by former Attorney General Charles C. Foti, Jr., is highlighting crucial information for investors in AstraZeneca PLC (NASDAQ: AZN) who may have incurred losses exceeding $100,000. The firm reminds those affected that they need to file lead plaintiff applications for their class...
Continue Reading
Important Class Action for GSK plc Investors: Know Your Rights
GSK Faces Class Action Lawsuit: Key Information for Investors Levi & Korsinsky, LLP has announced a class action securities lawsuit involving GSK plc, a well-known pharmaceutical company traded on the NYSE under the ticker GSK. This lawsuit is particularly significant for investors who have been adversely affected during a specified period concerning the securities of...
Continue Reading
Denny’s Fundraiser for No Kid Hungry: Making a Difference
Denny’s Annual Fundraiser for No Kid Hungry Returns Denny’s is excited to bring back its annual in-restaurant fundraiser to support No Kid Hungry, a national initiative focused on ending childhood hunger in the United States. This campaign will run for a designated period, allowing Denny's restaurants to make a meaningful difference by ensuring that children have...
Continue Reading